Ontology highlight
ABSTRACT:
SUBMITTER: Illangeswaran RSS
PROVIDER: S-EPMC6684879 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Pharmacogenomics and personalized medicine 20190802
Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab-ozogamicin, and CPX351 by the US Food and Drug ...[more]